Clinical Trial Update: EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating EMD 1201081 in combination with cetuximab in second-line, cetuximab-naive recurrent or metastatic squamous cell carcinoma of the head a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• Cetuximab (cetuximab)
• EMD 1201081

Snippet

Sponsor: EMD Serono | Conditions: Squamous Cell Carcinoma of the Head and Neck Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-07-29